AMG 193 (Anvumetostat, Figure 1) is an MTA-cooperative PRMT5 inhibitor currently in clinical development for the treatment of MTAP-deleted cancers.
Afuresertib is an oral, ATP-competitive pan-AKT inhibitor originally from GSK and now developed by Laekna; currently in late-stage trials for solid tumors (e.g., HR+/HER2- breast cancer and mCRPC).
Enarodustat is an orally active hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitor developed by Japan Tobacco for the treatment of renal anemia associated with chronic kidney disease (CKD).
Nerandomilast is a novel treatment option for adults with idiopathic pulmonary fibrosis (IPF), approved by the U.S. FDA on October 7, 2025.
Trans-3-hydroxy-L-proline is a noncanonical amino acid that plays a vital role in pharmaceutical development.
Brensocatib (Brinsupri™) was approved by the U.S. FDA on August 12, 2025, for the treatment of adults and children 12 years of age and older with non-cystic fibrosis bronchiectasis (NCFB).